Zata Pharmaceuticals, Inc.

Glsynthesis Inc.

Ivan Yanachkov

David R Tabatadze

George Edward Wright

The invention relates to a method for the detection of natural or modified nucleic acids by their sequence specific hybridization with charge-modified oligonucleotide probes having charge-modifying groups attached to their backbones. The charge-modifying groups partially or fully neutralize the net negative charge of the backbone of the oligonucleotide probes or render them with a net positive charge. The charge-modified oligonucleotide probes may or may not be labeled, for example, with fluorescent, visible or near-infrared dye, with radioactive or stable isotopes, or with high specific affinity binding groups. The charge-modified oligonucleotide probes facilitate the separation of their hybrids with the targeted nucleic acids from the unhybridized probes or from any other components of the analyzed sample. They also allow for the modification and optimization of the properties of the hybrids with the targeted nucleic acids, such as melting temperature, chromatographic properties and off-target specificity.

Detection method for natural and modified small nucleic acids

Compositions and compounds of nucleoside phosphoramidites and modified oligonucleotides, each comprising one or more charge-neutralizing moieties according to the formula V The nucleoside phosphoramidites permit facile attachment of the neutralizing moieties on the backbones of the modified oligonucleotides. The modified oligonucleotides can be used as therapeutic agents (i.e., oligotherapeutics) for the treatment of cancer, autoimmune disorders, genetic diseases, infectious diseases, neurological diseases, inflammatory diseases, metabolic diseases and others.

Phosphoramidite synthones for the synthesis of self-neutralizing oligonucleotide compounds

Compositions and compounds of nucleoside phosphoramidites and modified oligonucleotides, each comprising one or more charge-neutralizing moieties according to the formula V whereinrepresents the point of attachment to the nucleoside phosphoramidite or the oligonucleotide, optionally through a spacer group. The nucleoside phosphoramidites permit facile attachment of the neutralizing moieties on the backbones of the modified oligonucleotides. The modified oligonucleotides can be used as therapeutic agents (i.e., oligotherapeutics) for the treatment of cancer, autoimmune disorders, genetic diseases, infectious diseases, neurological diseases, inflammatory diseases, metabolic diseases and others.

The invention features compounds of formula I and methods of their use as antiplatelet and antithrombotic compounds: H/N=Q&#x3c7;2OOOO&#x39b;Q2-N, HR6/NIf)(^XMO-M&#x3b3;&#x3c4;OM&#xb0;&#x3c4;X1MQ')r(^rfHOOHHOOQHiN&#x3c7;iR2 Formula (I). 

Antithrombotic diadenosine tetraphosphates and related analogs

This invention features bis-amides of pyrophosphoric acid and bisphosphonic acids, their preparation, and their use in synthesis of P,P-dinucleoside tetraphosphates, tetraphosphonates, and related compounds.

Growing community of inventors

Shrewsbury, MA, United States of America

Ivan Yanachkov